☰

Wukun Liu, Ph.D.

Affiliations: 
2008-2012 School of Pharmacy Free University of Berlin 
 2012-2017 School of Medicine Johns Hopkins University, Baltimore, MD 
 2017- Nanjing University of Chinese Medicine 
Area:
Medicinal Chemistry
Website:
https://smls.njucm.edu.cn/2021/0728/c5309a79311/page.htm
Google:
"Wukun Liu"
Bio:

Wukun Liu received his PhD from the Free University of Berlin (2012) under the supervision of Prof. Ronald Gust and carried out postdoctoral research at Johns Hopkins University in Prof. Jun O. Liu’s laboratory. In 2017, he began his independent career at Nanjing University of Chinese Medicine, Nanjing, China. His current research interests are mainly focused on medicinal chemistry, particularly in the design, synthesis and mechanism study of gold- and platinum-based anticancer drugs.

Mean distance: (not calculated yet)
 
Tree Publications Similar researchers PubMed Report error

Parents

Sign in to add mentor
Ronald Gust grad student 2008-2012 Free University of Berlin
Jun O. Liu post-doc 2012-2017 Nanjing University of Traditional Chinese Medicine

Children

Sign in to add trainee

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Huang B, Xu Z, Liao D, et al. (2025) Synthesis and discovery of simplified pleurotin analogs bearing tricyclic core as novel thioredoxin reductase inhibitors. European Journal of Medicinal Chemistry. 285: 117242
Zheng T, Wang S, Liu W, et al. (2025) Targeting KAT6A/B as a New Therapeutic Strategy for Cancer Therapy. Journal of Medicinal Chemistry. 68: 1002-1020
Zhou L, Lu Y, Liu W, et al. (2024) Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice. Experimental Hematology & Oncology. 13: 26
Ma X, Wang Z, Li Y, et al. (2024) Metal complexes bearing EGFR-inhibiting ligands as promising anticancer agents. Medicinal Research Reviews
Lu Y, Sheng X, Liu C, et al. (2023) SERD-NHC-Au(I) complexes for dual targeting ER and TrxR to induce ICD in breast cancer. Pharmacological Research. 106731
Chang X, Bian M, Liu L, et al. (2022) Induction of immunogenic cell death by novel platinum-based anticancer agents. Pharmacological Research. 187: 106556
Lu Y, Ma X, Chang X, et al. (2022) Recent development of gold(I) and gold(III) complexes as therapeutic agents for cancer diseases. Chemical Society Reviews
Yang Z, Huang S, Liu Y, et al. (2022) Biotin-Targeted Au(I) Radiosensitizer for Cancer Synergistic Therapy by Intervening with Redox Homeostasis and Inducing Ferroptosis. Journal of Medicinal Chemistry
Xu Z, Xu J, Sun S, et al. (2022) Mecheliolide elicits ROS-mediated ERS driven immunogenic cell death in hepatocellular carcinoma. Redox Biology. 54: 102351
Xiao Q, Liu Y, Jiang G, et al. (2022) Heteroleptic Gold(I)-bisNHC complex with excellent activity in vitro, ex vivo and in vivo against endometrial cancer. European Journal of Medicinal Chemistry. 236: 114302
See more...